Hemophilia 2018: Current and Emerging Therapies

Attend in person

Thank you for signing up

You will receive a reminder email the day before the event.

Register Now

December 8, 2017, 1:00 PM

Georgia World Congress Center


Atlanta, GA


Maximum Of 1.5 AMA PRA Category 1 Credit(s)


Our panel of experts will explore the practical implications of the changing hemophilia treatment landscape. They will discuss optimal ways to integrate extended half-life (EHL) factor products into management, ongoing challenges to hemophilia care, and the development of novel small molecules as well as the latest in gene therapy.


Steven W. Pipe, MD

Professor of Pediatrics and Pathology, University of Michigan, Ann Arbor, Michigan, United States

Michael U. Callaghan, MD

Assistant Professor, Wayne State University, Detroit, Michigan, United States

Stacy E. Croteau, MD, MMS

Assistant Professor in Pediatrics, Harvard Medical School, Associate Director, Boston Hemophilia Center, Boston Children's Hospital, Boston, Massachusetts, United States

John Pasi, MB ChB, PhD, FRCP, FRCPath, FRCPCH

Professor of Haemostasis and Thrombosis, Barts and the London School of Medicine and Dentistry London, United Kingdom



Friday, December 8, 2017

12:30 PM - 1:00 PM

Registration and Lunch

1:00 PM - 1:05 PM

Welcome and Introductions

Steven W. Pipe, MD

1:05 PM - 1:20 PM

EHL Factor Products: Long-Term Efficacy and Safety

Stacy E. Croteau, MD, MMS

1:20 PM - 1:35 PM

Nonfactor Replacement Products: Data and Implications

Michael U. Callaghan, MD

1:35 PM - 1:50 PM

Gene Therapy: Present and Future

John Pasi, MB ChB, PhD, FRCP, FRCPath, FRCPCH

1:50 PM - 2:10 PM

Panel Discussion: What Do You Do Now?


2:10 PM - 2:30 PM

Question and Answer Session



Learning Objectives

Upon completion of this activity, participants will:

  • Have increased knowledge regarding
    • Advances in pressing issues in hemophilia, such as inhibitors, monitoring, or joint health
    • Outcomes from long-term efficacy and safety assessments of established EHL factor products
    • Clinical trial data from new/emerging EHL factor products and nonfactor replacement therapies
  • Demonstrate greater confidence in their ability to
    • Use EHL factor products appropriately in patients with hemophilia

Target Audience

This activity is intended for hematologists, pediatricians, and other healthcare professionals who treat patients with hemophilia.

Goal Statement

The goal of the activity is to discuss the latest advances in the management of hemophilia, including the evolving role of extended half-life factor products and emerging data on small molecule approaches and gene therapy.

Accreditation Statement

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credits Available:
Maximum Of 1.5 AMA PRA Category 1 Credit(s)

Medscape, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Partner Statement

Presented through a collaboration between the National Hemophilia Foundation and Medscape.


Georgia World Congress Center


Georgia World Congress Center, 285 Andrew Young International Blvd NW, Atlanta, GA 30313



Supported by independent educational grant from: